Ferric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalisations and exercise function in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, according to late breaking research presented in a Hot Line session today at ESC Congress 2023. 1 Previous studies have shown that FCM improves symptoms, quality of life and exercise capacity in patients with HFrEF and iron deficiency. 2,3 Further evidence is needed regarding its effects on clinical events.

https://www.miragenews.com/ferric-carboxymaltose-heart-failure-trial-fails-1073306/

#miragenews